850-851 / 2605
•
Dose (RBE) escalation and improved local control
(for intermediate-high risk patients)
•
Reduced toxicity for prostate irradiation (including
sexual function and secondary cancer)
•
Reduced toxicity for pelvic irradiation
•
Better tolerance of hypofractionation
•
Advantage for focal therapy
Potential benefit of Particles